AR and cancer: Aligned with this immunotherapeutic strategy, dual A2A/A2B AR antagonists, etrumadenant and M1069 (Figure 4), have being investigated across multiple cancer types, including prostate, colorectal, urothelial, and head and neck tumors, progressing to phase II trials.